Edition:
United Kingdom

Biomarin Pharmaceutical Inc - Pku gene therapy planned IND for 2H 2019


Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN PHARMACEUTICAL INC - PKU GENE THERAPY PLANNED IND FOR 2H 2019.BIOMARIN PHARMACEUTICAL INC - PHASE 3 STUDY OF VOSORITIDE IN CHILDREN IS NOW FULLY ENROLLED AND TOP LINE RESULTS ARE PLANNED FOR END OF 2019.BIOMARIN - BASED ON FDA FEEDBACK & INTERIM RESULTS, WILL TARGET 2H OF 2019 TO SUBMIT A BIOLOGIC LICENSE APPLICATION (BLA) FOR ACCELERATED APPROVAL..BIOMARIN PHARMACEUTICAL INC - BIOMARIN PLANS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR BMN 307 WITH FDA IN SECOND HALF OF 2019.